Results about GPR109A and NF-κB activation revealed the significant role of GPR109A in PD, these findings provide preliminary support for targeting the damaged intestinal barrier and activating the GRP109A receptor as novel PD therapies. Here, HCAR2 is linked to Parkinson disease.